1. Pragmatic approach, optimizing for speed:

- Reimbursement, pricing and dossier strategy for company’s 1st ever drug to market (oncology) which was 3rd to market with limited data, requiring pragmatic approach to price & reimbursement negotiations, balancing joint need for price and speed to reimbursement

- Development of reimbursement dossier to apply for 1st listing in positive list of reimbursed drugs (SL, Spezialitätenliste)

- Post-submission support for price and reimbursement negotiations for entire duration of negotiations until SL listing (11 months from dossier submission to SL listing)

2. ATMP with complex Managed Entry Agreement:

- Reimbursement, pricing, dossier and wider market access strategy for gene therapy

- Development of reimbursement dossier

- Post-submission support for price and reimbursement negotiations for entire duration of negotiations until reimbursement, incl. complex & innovative managed entry agreement

3. New dossier submission with multiple possible scenarios following failed price negotiation

- Reimbursement, pricing and dossier strategy for orphan drug (chronic CNS indication) in adult and pediatric indication with several potential subgroups impacting potential price range and reimbursement limitations

- Development of reimbursement dossier to apply for 1st listing in positive list of reimbursed drugs (SL, Spezialitätenliste)

4. Non-standard reimbursement pathway:

- Support during price and reimbursement negotiations directly with insurance companies

- Focus was on identifying Swiss comparator costs, incl. gap analysis
- Work included expert interviews, data landscaping, and commissioning proprietary analyses of Swiss data

5. Expert advice supporting in-licensing & Phase 2b/3 trial investment decisions

- Several drugs (onco, non-onco)

- Incl. competitive landscaping and data gap analysis

6. Devices, drug-device-combinations, lab tests

- Strategic pricing-, reimbursement - and market access advice

- Development and/or review of reimbursement dossiers for devices, lab tests and "general services" (medical technologies not covered by standard pathways, e.g. because they cut across several sectors of the Swiss health care system)